SCHEMBL957321

SCHEMBL957321

CCOC(=O)C1(CCCCCCOc2ccccc2)CO1

nearest known ligand 0.78

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.78
LMNA P02545 3/20 0.78
MAPK1 P28482 2/20 0.78
ABCB11 O95342 1/20 0.78
TDP1 Q9NUW8 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
GAA P10253 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 4/20 0.46
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 3/20 0.46
OPRM1 P35372 2/20 0.46
OPRD1 P41143 2/20 0.46
P4HB P07237 1/20 0.45
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11292121 1.00 MAPT (0.78) MAPTLMNAMAPK1ABCB11TDP1
SCHEMBL11298604 0.99 MAPT (0.76) MAPTLMNAMAPK1ABCB11TDP1
SCHEMBL11288785 0.95 MAPT (0.70) MAPTLMNAMAPK1ABCB11TDP1
SCHEMBL11292129 0.91 LMNA (0.64) MAPTLMNAMAPK1ABCB11TDP1
SCHEMBL14769764 0.90 MAPT (0.82) MAPTLMNAMAPK1ABCB11GAA
SCHEMBL11288224 0.88 MAPT (0.80) MAPTLMNAMAPK1ABCB11GAA
SCHEMBL11297622 0.88 ABCB11 (0.78) MAPTLMNAMAPK1ABCB11SMN1; SMN2
SCHEMBL955245 0.88 ABCB11 (0.78) MAPTLMNAMAPK1ABCB11SMN1; SMN2
SCHEMBL1578568 0.88 MAPT (0.78) MAPTLMNAMAPK1ABCB11GAA
Etomoxir SCHEMBL49075 0.88 ABCB11 (1.00) MAPTLMNAMAPK1ABCB11GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200330400-A1 METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 AND FATTY ACID METABOLISM INHIBITORS BERG LLC 2020-10-22 US claimed
WO-2017161205-A1 METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 AND FATTY ACID METABOLISM INHIBITORS BERG LLC (US) 2017-09-21 WO claimed
WO-2014018801-A1 DIAGNOSIS AND TREATMENT OF CANCER USING DIFFERENTIALLY EXPRESSED STARVATION MARKERS THE TEXAS A&M UNIVERSITY SYSTEM (US) 2014-01-30 WO claimed
WO-2013071029-A1 METHODS AND PRODUCTS FOR GENERATING OILS THE TEXAS A&M UNIVERSITY SYSTEM (US) 2013-05-16 WO claimed
US-20130056683-A1 COMPOSITIONS AND METHODS FOR PROMOTING FATTY ACID PRODUCTION IN PLANTS THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2013-03-07 US claimed
WO-2012135632-A2 METHODS OF TREATING A SUBJECT HAVING BEEN EXPOSED TO A CATASTROPHIC EVENT THE TEXAS A&M UNIVERSITY SYSTEM (US) 2012-10-04 WO claimed
EP-2486140-A2 COMPOSITIONS AND METHODS FOR PROMOTING FATTY ACID PRODUCTION IN PLANTS Regents of the University of Colorado (US) 2012-08-15 EP claimed
WO-2011043806-A2 COMPOSITIONS AND METHODS FOR PROMOTING FATTY ACID PRODUCTION IN PLANTS REGENTS OF THE UNIVERSITY OF COLORADO (US) 2011-04-14 WO claimed
US-20110078946-A1 COMPOSITIONS AND METHODS FOR PROMOTING FATTY ACID PRODUCTION IN PLANTS THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE 2011-04-07 US claimed
EP-1275390-B1 Medicament for treatment of heart failure WOLF HORST P O (DE) 2005-11-02 EP claimed
US-5739159-A Medicaments for the treatment of cardiac insufficiency WOLF HORST (DE) 1998-04-14 US claimed
EP-0231367-B1 USE OF OXIRANCARBOXYLIC ACIDS FOR THE TREATMENT OF HYPERLIPEMIA Wolf, Horst P.O., Dr. (DE) 1991-07-24 EP claimed
US-20200330400-A1 METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 AND FATTY ACID METABOLISM INHIBITORS BERG LLC 2020-10-22 US disclosed
US-10041096-B2 Methods and products for generating oils TEXAS A & M UNIV SYS (US) 2018-08-07 US disclosed
WO-2017161205-A1 METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 AND FATTY ACID METABOLISM INHIBITORS BERG LLC (US) 2017-09-21 WO disclosed
US-20150231237-A1 METHODS AND PRODUCTS FOR TREATING PROLIFERATIVE DISEASES THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2015-08-20 US disclosed
US-20020198382-A1 Oxiran carboxylic acids for the treatment of diabetes HORST P.O. WOLF (DE) 2002-12-26 US disclosed
US-6013666-A ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION Jew, Sang Sup (KR) 2000-01-11 US disclosed
US-5739159-A Medicaments for the treatment of cardiac insufficiency WOLF HORST (DE) 1998-04-14 US disclosed
WO-1998000422-A1 OXIRANE CARBOXYLIC ACID DERIVATIVE AND ITS MANUFACTURING METHOD JEW SANG SUP (KR) 1998-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198382-A1 Oxiran carboxylic acids for the treatment of diabetes GPR119, SLC5A2, SLC2A4 MAPT 4759/4885LMNA 3609/4885MAPK1 1907/4885
US-20200330400-A1 METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 AND FATTY ACID METABOLISM INHIBITORS CPT1B, CPT2, CPT1A MAPT 2554/4885LMNA 1667/4885MAPK1 3874/4885
US-10041096-B2 Methods and products for generating oils LIPE, FASN, LIPC MAPT 4545/4885LMNA 4267/4885MAPK1 4402/4885
US-20150231237-A1 METHODS AND PRODUCTS FOR TREATING PROLIFERATIVE DISEASES BECN1, G6PD, VHL MAPT 2123/4885LMNA 3405/4885MAPK1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.